With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs
December 07, 2017 at 10:38 AM EST
The six-year-old Cambridge company saw its market cap jump more than $2.5 billion after announcing positive trial data, making it the fifth most valuable drugmaker headquartered in the state.
